Literature DB >> 22556142

Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat.

Jeannie Chan1, Francis E Sharkey, Rampratap S Kushwaha, Jane F VandeBerg, John L VandeBerg.   

Abstract

Plasma VLDL and LDL cholesterol were markedly elevated (>40-fold) in high-responding opossums, but moderately elevated (6-fold) in low-responding opossums after they had consumed a high-cholesterol and high-fat diet for 24 wk. In both high- and low-responding opossums, plasma triglycerides were slightly elevated, threefold and twofold, respectively. Dietary challenge also induced fatty livers in high responders, but not in low responders. We studied the lipid composition, histopathological features, and gene expression patterns of the fatty livers. Free cholesterol (2-fold), esterified cholesterol (11-fold), and triglycerides (2-fold) were higher in the livers of high responders than those in low responders, whereas free fatty acid levels were similar. The fatty livers of high responders showed extensive lobular disarray by histology. Inflammatory cells and ballooned hepatocytes were also present, as were perisinusoidal fibrosis and ductular proliferation. In contrast, liver histology was normal in low responders. Hepatic gene expression revealed differences associated with the development of steatohepatitis in high responders. The accumulation of hepatic cholesterol was concomitant with upregulation of the HMGCR gene and downregulation of the CYP27A1, ABCG8, and ABCB4 genes. Genes involved in inflammation (TNF, NFKB1, and COX2) and in oxidative stress (CYBA and NCF1) were upregulated. Upregulation of the growth factor genes (PDGF and TGFB1) and collagen genes (Col1A1, Col3A1, and Col4A1) was consistent with fibrosis. Some of the histological characteristics of the fatty livers of high-responding opossums imitate those in the livers of humans with nonalcoholic steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22556142      PMCID: PMC3404580          DOI: 10.1152/ajpgi.00415.2011

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.871


  41 in total

Review 1.  NADPH oxidase in the liver: defensive, offensive, or fibrogenic?

Authors:  Samuele De Minicis; Ramón Bataller; David A Brenner
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

Review 2.  Regulation of intracellular cholesterol metabolism.

Authors:  R Sato; T Takano
Journal:  Cell Struct Funct       Date:  1995-12       Impact factor: 2.212

3.  The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes.

Authors:  Z M Yao; D E Vance
Journal:  J Biol Chem       Date:  1988-02-25       Impact factor: 5.157

4.  The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver.

Authors:  T Gerloff; B Stieger; B Hagenbuch; J Madon; L Landmann; J Roth; A F Hofmann; P J Meier
Journal:  J Biol Chem       Date:  1998-04-17       Impact factor: 5.157

5.  Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis.

Authors:  Montserrat Marí; Francisco Caballero; Anna Colell; Albert Morales; Juan Caballeria; Anna Fernandez; Carlos Enrich; José C Fernandez-Checa; Carmen García-Ruiz
Journal:  Cell Metab       Date:  2006-09       Impact factor: 27.287

6.  Dramatic differences in lipoprotein composition among gray short-tailed opossums (Monodelphis domestica) fed a high cholesterol/saturated fat diet.

Authors:  D L Rainwater; J L VandeBerg
Journal:  Biochim Biophys Acta       Date:  1992-06-22

7.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

8.  Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.

Authors:  J J Smit; A H Schinkel; R P Oude Elferink; A K Groen; E Wagenaar; L van Deemter; C A Mol; R Ottenhoff; N M van der Lugt; M A van Roon
Journal:  Cell       Date:  1993-11-05       Impact factor: 41.582

9.  Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/ - ) mice harbouring chronic cholangitis.

Authors:  Karl Esten Nakken; Ståle Nygård; Terese Haaland; Knut Erik Berge; Kristin Arnkvaern; Annlaug Ødegaard; Knut Jørgen Labori; Morten G Raeder
Journal:  Scand J Gastroenterol       Date:  2007-10       Impact factor: 2.423

10.  A lipidomic analysis of nonalcoholic fatty liver disease.

Authors:  Puneet Puri; Rebecca A Baillie; Michelle M Wiest; Faridoddin Mirshahi; Jayanta Choudhury; Onpan Cheung; Carol Sargeant; Melissa J Contos; Arun J Sanyal
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

View more
  10 in total

1.  Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.

Authors:  George N Ioannou; Derrick M Van Rooyen; Christopher Savard; W Geoffrey Haigh; Matthew M Yeh; Narci C Teoh; Geoffrey C Farrell
Journal:  J Lipid Res       Date:  2014-12-17       Impact factor: 5.922

2.  Evolution of the Genotype-to-Phenotype Map and the Cost of Pleiotropy in Mammals.

Authors:  Arthur Porto; Ryan Schmelter; John L VandeBerg; Gabriel Marroig; James M Cheverud
Journal:  Genetics       Date:  2016-10-26       Impact factor: 4.562

Review 3.  Nonhuman Primates and Translational Research-Cardiovascular Disease.

Authors:  Laura A Cox; Michael Olivier; Kimberly Spradling-Reeves; Genesio M Karere; Anthony G Comuzzie; John L VandeBerg
Journal:  ILAR J       Date:  2017-12-01

4.  Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients.

Authors:  Lu Liu; Yong Yu; Meng Zhao; Dongmei Zheng; Xu Zhang; Qingbo Guan; Chao Xu; Ling Gao; Jiajun Zhao; Haiqing Zhang
Journal:  Int J Endocrinol       Date:  2017-04-04       Impact factor: 3.257

5.  Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.

Authors:  Ahad Eshraghian
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

Review 6.  Is there a role of lipid-lowering therapies in the management of fatty liver disease?

Authors:  Ismini Tzanaki; Aris P Agouridis; Michael S Kostapanos
Journal:  World J Hepatol       Date:  2022-01-27

7.  NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.

Authors:  Geoffrey C Farrell; Derrick van Rooyen; Lay Gan; Shivrakumar Chitturi
Journal:  Gut Liver       Date:  2012-04-17       Impact factor: 4.519

Review 8.  In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD).

Authors:  Giridhar Kanuri; Ina Bergheim
Journal:  Int J Mol Sci       Date:  2013-06-05       Impact factor: 5.923

9.  Cholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease.

Authors:  Linqiang Zhang; Zhiguo Zhang; Yunhai Li; Shasha Liao; Xiaoyun Wu; Qing Chang; Bin Liang
Journal:  Sci Rep       Date:  2015-11-02       Impact factor: 4.379

10.  Tree shrew (Tupaia belangeri chinensis), a novel non-obese animal model of non-alcoholic fatty liver disease.

Authors:  Linqiang Zhang; Xiaoyun Wu; Shasha Liao; Yunhai Li; Zhiguo Zhang; Qing Chang; Ruyue Xiao; Bin Liang
Journal:  Biol Open       Date:  2016-10-15       Impact factor: 2.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.